Can Brivaracetam Reverse Memory Impairment in Alzheimer’s Patients?
While Brivaracetam is being evaluated as an adjunctive therapy in patients diagnosed with Epilepsy and partial onset seizures, animal models have piqued the curiosity of R&D experts as to...
View ArticleSonidegib FDA Approved as Once Daily Treatment for Locally Advanced Basal...
On July 24, 2015 the FDA approved Sonidegib, marketed by Novartis AG as the once daily pill Odomzoa for the treatment of locally advanced basal cell carcinoma. Specifically for patients with locally...
View ArticlePaliperidone Approved as Quarterly Therapy for Patients with Schizophrenia
The FDA gave the green light in late May 2015 with their approval of a quarterly dosing schedule of Paliperidone Palmitate, also known as Invega Trinza. Marketed by Janssen Pharmaceuticals this novel...
View ArticleCan Brivaracetam Reverse Memory Impairment in Alzheimer’s Patients?
While Brivaracetam is being evaluated as an adjunctive therapy in patients diagnosed with Epilepsy and partial onset seizures, animal models have piqued the curiosity of R&D experts as to...
View ArticleSonidegib FDA Approved as Once Daily Treatment for Locally Advanced Basal...
On July 24, 2015 the FDA approved Sonidegib, marketed by Novartis AG as the once daily pill Odomzoa for the treatment of locally advanced basal cell carcinoma. Specifically for patients with locally...
View ArticlePaliperidone Approved as Quarterly Therapy for Patients with Schizophrenia
The FDA gave the green light in late May 2015 with their approval of a quarterly dosing schedule of Paliperidone Palmitate, also known as Invega Trinza. Marketed by Janssen Pharmaceuticals this novel...
View Article
More Pages to Explore .....